CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10
November 05, 2021 15:25 ET
|
Eyenovia, Inc.
Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be...
Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11
November 04, 2021 16:05 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia
November 04, 2021 08:00 ET
|
Eyenovia, Inc.
Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022 Presbyopia represents a multi-billion-dollar market opportunity in the U.S. alone NEW YORK, Nov. 04, 2021 ...
Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA
October 25, 2021 08:00 ET
|
Eyenovia, Inc.
Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers, and ophthalmic dispensers Company received Complete Response Letter...
Eyenovia Reports Second Quarter 2021 Financial Results
August 11, 2021 16:05 ET
|
Eyenovia, Inc.
Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia Company on track to initiate second Phase 3 presbyopia trial, VISION-2, by...
Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11
August 04, 2021 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...
Eyenovia to Participate in Two Upcoming Investor Conferences
July 07, 2021 16:01 ET
|
Eyenovia, Inc.
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...
Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
June 15, 2021 08:00 ET
|
Eyenovia, Inc.
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia
May 25, 2021 09:03 ET
|
Eyenovia, Inc.
Primary endpoint was achieved with well-tolerated micro-array print (MAP™) safety profile Upcoming key 12 month milestones include Mydcombi PDUFA; Vision 2 Phase 3 trial results and completion of...
Eyenovia Reports First Quarter 2021 Financial Results
May 12, 2021 16:05 ET
|
Eyenovia, Inc.
MydCombi PDUFA date confirmed for October 28, 2021 Completed patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; top-line data on track for Q2 Secures...